AMA Thurs 6/25/20: Intercollegiate Psychedelics Network Co-Founder and COMPASS Pathways Intern

Ask-Me-Anything (AMA) on Thurs Jun 25 from 5-6pm PT

We are very lucky to announce that Rahul Sood, co-founder of Intercollegiate Psychedelics Network, is joining as a special guest to do an AMA on Thurs Jun 25 from 5-6pm PT.

Rahul is a recent graduate from the Life Science and Management Program at the University of Pennsylvania/Wharton. He is interested in mental wellness and exploring this topic through the lens of science, business and philosophy. He has interned at mental health company COMPASS Pathways, a mental health company developing psilocybin therapy for treatment-resistant depression, working on digital therapeutics for mental health. In 2019, Rahul co-founded the Intercollegiate Psychedelics Network (IPN) with 6 other cofounders from Harvard, Penn and Princeton to co-create a youth-led umbrella organization dedicated to fostering the development of students into the next generation of diverse and interdisciplinary leaders in the field of psychedelics.

The Intercollegiate Psychedelics Network (IPN) is a value-driven organization aim to provide support and catalyze organizational change from the ground up. It is a bio-inspired network that has an organizational structure of cross-functional teams (Mushroom Caps) that lead different effort and is organization by a Mycelial leadership. To learn more about IPN’s missions, principles and structure see:

Topics Rahul can speak to:

  1. Psychedelics movement for young people
  2. R&D in psychedelics; biotech activity in psychedelics
  3. Startups in psychedelics

IPN is also recruiting leaders - you can apply here:

what’s the best way for young people to get involved with the psychedelics movement??

How did you become interested in the psychedelic movement?

Thanks for doing this!

What would you say are the top few things most people do not know about psychedelics and psychedelic medicine?

For example if one had to convince their parents or grandparents that these therapies are legit, what would be the key points you’d recommend bringing up?

  • Do you know what the timeline is for psilocybin with COMPASS?
  • Do you know if COMPASS has any IP around psilocybin?
  • Where is COMPASS running its phase 2 clinical trials?
  • I know Usona is also developing psilocybin, but Usona is in the US and COMPASS is in England. Could you talk a bit about how these two organizations fit together going forward? What’s the difference in the trials being run by the two orgs, and is there a difference in the psilocybin formulation/manufacturing/IP/protocol? Are we going to get FDA approval of both these org’s psilocybin treatments which may be different? How are they different?

Thank you so much!!

1 Like

Hi Rahul, thank you for starting something as cool as the Intercollegiate Psychedelics Network. This looks like a very worthwhile movement for young people. I am happy to see this. I have one question for you, what is the psilocybin treatment protocol that will be included in the regulatory approval applications? Will it be like MDMA where it’s psychedelic-assisted psychotherapy, and if so what does the protocol look like? Do you see future regulatory approvals being made for the medication itself without the stringent psychotherapy protocols?

IPN looks so cool! Are only students eligible to apply to join?

have you thought about bridging the older generation of psychedelics advocates/people (from 50s, 60s, etc) with the current college students? I bet there would be some gaps in culture, vision, understanding, yet its important for everyone to come together

do you think ketamine infusions are part of psychedelic medicine?

Thanks for being here Rahul! I’m curious…

  1. What is currently keeping larger pharmaceutical companies from entering the psilocybin space?

  2. COMPASS recently closed a large series B round, do you think this will spark an influx of other companies into this space? If so, do you envision clear skies ahead, or are there other potential barriers you are worried about?

  3. Both ketamine and psilocybin are being targeted for TRD. Why is the community using these drugs to target TRD when we could be targeting depression in general and having ketamine and psilocybin be first-line therapies?

Thank you for your time!

I’m curious, how does your experience working with younger people so far differ from your experience working/collaborating with older people?

Thank you so much Osmind for having me! Really look forward to answering these questions :slight_smile:

If anyone is interested in joining a youth-led psychedelics organization please check out IPN ( we are recruiting!


Thanks for the question, Sans! Here is my reply:

Thank you for these questions! Here is my answer in a couple of parts:


Hi Aviato here my reply, thank you for your question :slight_smile:

Cheers for the questions!

Hi Ezra,

Nope you don’t have to be a student - just interested in the intercollegiate space! Especially for IPN leadership we encourage anyone to apply.

That being said, our main vision is to cultivate a network within academic that is youth-led. So you don’t have to be a student but interested in developing this type of network.